UK veterans gain expanded NHS mental and physical health support programmes

Veterans in the UK can now access expanded mental and physical health support through dedicated NHS programmes. These services include Op COURAGE for psychological care and Op RESTORE for rehabilitation, with tailored options available across England, Scotland, Wales, and Northern Ireland. Meanwhile, concerns have been raised about the anti-malarial drug mefloquine and its potential long-term effects on former service personnel.

The Ministry of Defence (MOD) and NHS England have strengthened collaboration to address veterans' health needs. Through the Armed Forces Clinical Reference Group, they have reviewed how mefloquine’s side effects are managed. The drug, still recommended by the World Health Organisation, requires careful monitoring, as its symptoms can mimic acute psychiatric conditions. Clinicians are now advised to take detailed drug and alcohol histories, including past mefloquine use, before diagnosing patients.

Op COURAGE offers NHS talking therapies for veterans in England struggling with PTSD, depression, or anxiety. For physical injuries, Op RESTORE provides specialist rehabilitation. Similar services exist in Scotland (via NHS Scotland veterans' pathways), Wales (NHS Wales Veterans Service), and Northern Ireland (NHS NI Veterans Health), though each region administers its own system. Veterans can seek help through their GP or self-refer to these programmes.

The issue of mefloquine’s impact gained attention after Sir Julian Lewis, Conservative MP for New Forest East, highlighted the need for NHS staff to recognise veterans' heightened risk of suicidal ideation linked to the drug. Both the MOD and NHS follow NICE guidelines for its prescription and treatment. Any side effects from mefloquine are addressed through individual clinical assessments, ensuring tailored care based on symptoms.

Veterans now have clearer routes to mental and physical health support, with region-specific NHS services available across the UK. The MOD and NHS continue to monitor mefloquine’s effects, ensuring clinicians follow updated guidance for diagnosis and treatment. These measures aim to provide targeted care for those who have served in the armed forces.